GlassScriptPhysician profile
Katie Snell
NPI 1184863987
$1,813.27
in general payments reported to CMS, 2019-2025
13 companies · $212 in 2025
The $212 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,324 · 2023: $238 · 2024: $39.22 · 2025: $212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $489.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $489.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| G1 Therapeutics, INC. | $1,323.78 | 2022 | |
| Gilead Sciences, INC. | $203.80 | 2023-2025 | Trodelvy, Descovy |
| Abbvie INC. | $45.03 | 2023-2025 | |
| Astellas Pharma US INC | $32.69 | 2025 | Vyloy |
| Sobi, INC | $29.69 | 2025 | |
| Genzyme Corporation | $29.63 | 2025 | |
| Karyopharm Therapeutics INC. | $29.44 | 2025 | Xpovio |
| Pfizer INC. | $27.39 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $25.63 | 2024 | |
| Genentech USA, INC. | $19.17 | 2023 | Lunsumio, Polivy, Perjeta |
| Beone Medicines USA, INC. | $16.95 | 2025 | Tevimbra |
| Merck Sharp & Dohme LLC | $16.48 | 2025 | Keytruda Qlex, Keytruda |
| Janssen Biotech, INC. | $13.59 | 2024 | Talvey, Tecvayli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Snell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.